An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cerus Corporation (Nasdaq:CERS) announced its participation in the 33rd Regional International Society of Blood Transfusion Congress in Sweden. The conference marks the first in-person event since 2019. Cerus will present abstracts and hold a lunch symposium on pathogen reduced products and transfusion safety. The company will also have representatives at booth #2716.
Positive
None.
Negative
None.
Symposium and Abstracts Highlight Data from Studies of INTERCEPT Platelets and Plasma as well as Developmental Programs
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. This year marks the first time the conference has taken place in person since 2019.
The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Time (CET).
Implementation of pathogen reduced products: considerations from the Canadian perspective and first experiences.
Improving patient safety through pathogen inactivation: the Stanford experience.
Strategies to reduce transfusion-transmitted bacterial infections: screening, pathogen inactivation, and cold stored platelets components.
Wednesday, June 21, 2023 – 9:15 a.m.– In Vitro Biochemical and Functional Comparison of Amotosalen-UVA-Treated Buffy-Coat Platelet Concentrates Stored in PAS-C Or PAS-E Additive Solution up to 7 Days
Poster Presentations
Held between Sunday, June 18 and Tuesday, June 20, 2023
Platelet Safety Measures in Sweden: An Assessment of Current Practices and Comparison with International Practices
In Vitro Biochemical and Functional Characteristics of Stored (Double-Dose) Buffy-Coat Platelet Concentrates Treated With Amotosalen and a Prototype UVA Light-Emitting Diode Illuminator
Evaluation of the In Vitro Properties Out to 7 Days of Buffy Coat Platelets Stored in PAS C Or PAS E and Treated With Amotosalen and a Prototype LED UVA Light Source
Initial Experience of Switching Pathogen Inactivation System With Extended Platelet Shelf Life
Transfusion of Amotosalen-UVA Pathogen Reduced Platelet Components to Mature and Premature Neonatal Infants
Amotosalen/UVA Light Pathogen Reduced Plasma from Previously Quarantined Units Stored for Two Years
A Pilot Study Tracking Pathogen Reduced RBCs In Vivo Using Surface Acridine and Biotin Flow Cytometric Markers
The full program of Cerus-related abstracts can be found at the following link: https://interceptbloodsystem.com/sites/default/files/resources/2023_isbt_abstractbook_final.pdf.
Cerus representatives will be in the exhibition area at booth #2716.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.